Summary & Overview
CPT 82016: Qualitative Acylcarnitines Metabolic Screen
CPT code 82016 represents a qualitative acylcarnitines laboratory test performed on plasma, serum, or urine to detect abnormal acylcarnitine profiles associated with inborn errors of metabolism. The test is clinically important as a component of newborn metabolic screening and for evaluating suspected metabolic disorders across age groups. Nationally, this code underpins lab-based diagnostic pathways that affect neonatal screening programs and specialist metabolic evaluations.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for ordering the test, typical sites of service, and which payers commonly cover this type of laboratory service. The publication also summarizes benchmark considerations, common billing modifiers, and policy themes relevant to laboratory reimbursement and medical necessity criteria.
This article is written for a national audience of clinicians, billing professionals, and policy analysts. It provides concise background on the clinical utility of qualitative acylcarnitine testing, highlights payer coverage scope, and outlines what to expect in terms of administrative coding and policy direction. Data not available in the input are noted where applicable.
Billing Code Overview
CPT code 82016 describes a qualitative acylcarnitines laboratory test. The analysis detects and qualitatively assesses acylcarnitine profiles in plasma, serum, or urine, commonly used to screen for inborn errors of metabolism, including as part of newborn screening programs.
Service Type: Laboratory test — qualitative metabolic screen
Typical Site of Service: Clinical laboratory or hospital laboratory; specimens may be collected in inpatient, outpatient, or newborn screening settings
Clinical & Coding Specifications
Clinical Context
A full-term newborn in a hospital nursery undergoes routine newborn screening within 24–48 hours of life. A neonatal nurse collects a blood sample by heel-stick onto a filter paper card and also prepares a small plasma/serum aliquot if the clinician requests targeted metabolic testing. The attending pediatrician orders 82016 for qualitative acylcarnitine analysis on plasma/serum to screen for inborn errors of metabolism (such as fatty acid oxidation defects and organic acidemias) after an initial abnormal dried blood spot result or when the infant shows signs of hypoglycemia, lethargy, poor feeding, or unexplained metabolic acidosis. The specimen is labeled with patient identifiers, sent to the hospital laboratory or a reference lab, and processed using tandem mass spectrometry or other qualitative methods. Results are reviewed by the pediatrician and a metabolic specialist when abnormal; positive or suspicious findings prompt confirmatory quantitative testing, genetic counseling referral, and notification of the newborn’s caregivers.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | When reporting only the physician/pathologist interpretation of the lab test separate from the facility/lab technical component. |